Navigation Links
Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug

patients were assessed as clinically cured at day 14 compared to 36% of Nystatin patients. Complete or partial responses at day 14 were observed in 95% of PAC-113 patients and 87% of Nystatin patients in the same population. Results also confirm that PAC-113 was generally safe and well-tolerated.

"We are very encouraged with these clinical results and expect that optimization of PAC-113 dose and formulation, as planned in the next Phase II trial, will further enhance clinical efficacy. We believe that these efforts in conjunction with the product's competitive advantages over existing treatments for oral candidiasis make it an excellent drug candidate to take into late stage studies," said Duffy DuFresne, President & CEO of Pacgen.

About PAC-113

PAC-113 is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva. This peptide alters the permeability of fungal cell membranes causing cell death. In addition, PAC-113 also interacts with fungal mitochondria causing production of reactive oxygen species that lead to fungal cell destruction. This activity is unique to histatin proteins.

Current treatments for Candida infections are not effective in eliminating the infection, can have serious side effects, have significant potential for drug interaction, and/or do not prevent the development of drug-resistant fungal infection. PAC-113 is easily administered and well-tolerated by patients as it is formulated as a sugar-free, pleasant tasting, non-viscous mouthrinse with a neutral pH. It also has a prolonged half-life in the saliva giving it the potential to extend the duration of the therapeutic effect, increasing the cure rate and reducing the time to relapse.

About Candida Infection

Candida albicans is the most common fungal pathogen among immune-compromised, hospitalized patients, accounting for roughly 50-60% of all bloodstream fungal isolates. Opportunistic growth of Candida
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/3/2015)... NEWPORT NEWS, Va. , Aug. 3, 2015 ... will be joining Orthopaedic & Spine Center ... help them to manage their chronic pain through ... Dr. Robinson is a Fellowship-trained, certified medical ... and pain medicine. His vast experience ranges from ...
(Date:8/3/2015)... SINGAPORE , Aug. 3, 2015 ... Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a ... today announced financial results for its first fiscal ... Quarter Highlights and Recent Developments: ... progress in improving its cost structure, driven by ...
(Date:8/3/2015)... , Aug. 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... host its Second Quarter 2015 Investor Conference Call and ... The call will cover an update on ... quarter 2015 financials. A press release detailing the information ... the afternoon of Monday, August 10. Investors and the ...
Breaking Medicine Technology:Orthopaedic & Spine Center Introduces New Pain Psychologist 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2
... BELGRADE, Mont., July 26, 2011 Bacterin ... a leader in the development of revolutionary bone graft material ... call on Thursday, August 11, at 4:30 p.m. Eastern time ... 2011. Financial results will be issued in a press release ...
... America, Inc. today announced plans to debut expanded software ... EasyCell® assistant Automated Cell Imaging Analyzer during ... Conference and Clinical Lab Expo July 24 - 28 ... hematology portfolio can be seen at Sysmex,s exhibit booth, ...
Cached Medicine Technology:Bacterin Sets Second Quarter 2011 Conference Call for Thursday, August 11, 2011 at 4:30 p.m. ET 2Sysmex America to Debut Expanded Software Products for Middleware and Cell Image Analysis at AACC 2011 2
(Date:8/3/2015)... ... August 03, 2015 , ... BESLER Consulting today announced ... Awards. , The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, ... the launch of their Readmissions Analytics product was selected as one of four ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today welcomed ... accepted for review OPKO’s New Drug Application for a new treatment for chronic ...
(Date:8/3/2015)... , ... August 03, 2015 , ... The art of ... Learning from her grandmother’s side at a young age, Nasreen Zereshki was extremely eager ... decided to share her cookbook Recipes from My Persian Kitchen with the world. , ...
(Date:8/3/2015)... ... 2015 , ... The U.S. Food and Drug Administration (FDA) recently approved a ... acid, which occurs naturally in the body and helps absorb and breakdown fat cells. ... the body. These are invasive procedures and very expensive for most people. Now with ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Dignity Health ... Health Arizona General Hospital Emergency Room – Gilbert, opening in August. The new ... this year in the West Valley. , “Dr. Baldwin is an excellent leader ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
... 8 Medivation, Inc.,(Nasdaq: MDVN ) today announced ... at the 27th Annual J.P. Morgan Healthcare,Conference on Wednesday, January ... Hotel in San Francisco. , Dr. ... programs for Dimebon for Alzheimer,s and Huntington,s diseases and,MDV3100 for ...
... announced today that Erik D. Olson has been named ... & Human Services Policy program. Olson, who was formerly ... Committee on Environment and Public Works, brings nearly 25 ... to Pew. "We are excited to be joined by ...
... be used when assessing traditional risk factors, experts say , , ... or "biomarkers" -- of inflammation may provide useful information when ... says. , "If you are very high or very low ... study lead author Dr. Vijay Nambi, a cardiologist at the ...
... Christine Siu and Jason Brown, Ph.D. Promoted to Vice ... Thomas, McNerney & Partners, a health care venture capital ... companies, today announced the promotion of three members of ... to Principal. Christine Siu and Jason Brown have ...
... ) announces the following Webcast: , What: Heska Corporation ... Year-End 2008 Earnings Conference Call on the Web, ... Where: www.heska.com (click on the Q4 and Year-End 2008 Earnings, ... of this website)., How: Live over the Internet ...
... 8 A proposal by the State of Indiana ... has prompted the 125,000-member American Legion Department of Indiana ... in order to organize and coordinate its members, nearly ... more than $50,000 in direct and in-kind support to ...
Cached Medicine News:Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3Health News:Thomas, McNerney & Partners Promotes Three Members of Its Investment Team 2Health News:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast 2
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
HDL Cholesterol (PEG) Precip. Reagent + 5 ml of 50 mg/dl cholesterol std....
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
Medicine Products: